Company intelligence

ALVO

Alvotech · NASDAQ · Healthcare

Price$5.45-3.02% · −$0.17

Market cap1.84BEquity value

P / E-9.2Trailing ratio

Volume750.79KLatest session

Market data

ALVO price chart

TradingView

Related signals

1 min delayed

Browse public ALVO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ALVOSep 16, 2026-1.39% since signal

Barclays Upgrades Alvotech to Overweight with $8 Target, ALVO Rises

Barclays upgraded Alvotech (ALVO) to Overweight with an $8 target, signaling potential upside. The stock gained about 7.8% to $5.41 on the news, suggesting near-term upside. The broader market strengthened, with the Nasdaq up around 150 points, while LuxExperience posted mixed Q4 results and shares rose on the session.

View signal analysis

ALVONov 3, 2025-2.91% since signal

Alvotech Shares Plunge 33% After FDA Flags Issues

ALVO received a complete response letter (CRL) from the FDA. Deficiencies noted in the BLA for AVT05 biosimilar to Simponi. Total revenue outlook for 2025 revised to $570-$600 million. ALVO stock dropped 33.99% to $5.05 following the news. Current FDA approvals for a Simponi biosimilar remain unachieved.

View signal analysis

Research